Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Baselga

Showing results (21-30 of 168) with videos related to

Pageof 17
Sort By:
Journal of Mammary Gland Biology and Neoplasia|March 8, 2000
The ErbB receptors as targets for breast cancer therapyJ Albanell, J Baselga
Journal of Mammary Gland Biology and Neoplasia|April 1, 1997
Type I receptor tyrosine kinases as targets for therapy in breast cancerJ Baselga, J Mendelsohn
Oncogene|June 28, 2001
The EGF receptor family as targets for cancer therapyJ Mendelsohn, J Baselga
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Mechanism of action of anti-HER2 monoclonal antibodiesJ Baselga, J Albanell
Drugs of Today (Barcelona, Spain : 1998)|September 16, 2003
Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancerJ Albanell, J Baselga
Drugs|December 29, 2000
ZD1839 ('Iressa') as an anticancer agentJ Baselga, S D Averbuch
The Oncologist|May 11, 2001
Weekly docetaxel in breast cancer: applying clinical data to patient therapyJ Baselga, J M Tabernero
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
The impact of cancer in Spain: consequences for cancer prevention and careJ M Borras, J Baselga
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2008
The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical OncologyJ Baselga, H J Senn,
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Pharmacodynamic endpoints in primary breast cancerS Di Cosimo, J Baselga
Pageof 17

Showing results (21-30 of 168) with videos related to

Sort By:
Pageof 17
Journal of Mammary Gland Biology and Neoplasia|March 8, 2000
The ErbB receptors as targets for breast cancer therapyJ Albanell, J Baselga
Journal of Mammary Gland Biology and Neoplasia|April 1, 1997
Type I receptor tyrosine kinases as targets for therapy in breast cancerJ Baselga, J Mendelsohn
Oncogene|June 28, 2001
The EGF receptor family as targets for cancer therapyJ Mendelsohn, J Baselga
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 28, 2001
Mechanism of action of anti-HER2 monoclonal antibodiesJ Baselga, J Albanell
Drugs of Today (Barcelona, Spain : 1998)|September 16, 2003
Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancerJ Albanell, J Baselga
Drugs|December 29, 2000
ZD1839 ('Iressa') as an anticancer agentJ Baselga, S D Averbuch
The Oncologist|May 11, 2001
Weekly docetaxel in breast cancer: applying clinical data to patient therapyJ Baselga, J M Tabernero
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
The impact of cancer in Spain: consequences for cancer prevention and careJ M Borras, J Baselga
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 30, 2008
The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical OncologyJ Baselga, H J Senn,
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Pharmacodynamic endpoints in primary breast cancerS Di Cosimo, J Baselga
Pageof 17